Compare VWAV & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VWAV | PEPG |
|---|---|---|
| Founded | 2024 | 2018 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 121.7M |
| IPO Year | N/A | 2022 |
| Metric | VWAV | PEPG |
|---|---|---|
| Price | $1.32 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.17 |
| AVG Volume (30 Days) | 633.2K | ★ 1.1M |
| Earning Date | 05-18-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $1.01 |
| 52 Week High | $15.80 | $7.80 |
| Indicator | VWAV | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 71.75 |
| Support Level | N/A | $1.47 |
| Resistance Level | N/A | $7.10 |
| Average True Range (ATR) | 0.00 | 0.20 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 90.98 |
VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.